Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Alvotech ( (ALVO) ) is now available.
On July 1, 2025, Alvotech announced a commercialization agreement with Advanz Pharma for the distribution and supply of AVT10, a biosimilar candidate to Cimzia, in Europe. This agreement strengthens Alvotech’s strategic position in the biosimilar market and aims to expand access to high-quality biologics in Europe, potentially impacting the market share of existing treatments for chronic rheumatic diseases.
The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s score is primarily influenced by its financial performance, which indicates rapid growth but significant financial instability. The earnings call provided a positive outlook with raised guidance and strategic product launches. However, technical analysis shows bearish signals and valuation is moderately high, affecting the overall score.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide. The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products through a fully integrated approach. Alvotech’s pipeline includes biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and it has formed strategic partnerships to expand its reach globally.
Average Trading Volume: 205,531
Technical Sentiment Signal: Sell
Current Market Cap: $2.76B
Find detailed analytics on ALVO stock on TipRanks’ Stock Analysis page.